March 22nd, 2004


(no subject)
FDA Issues Warning on Some Antidepressants
Government Urges Close Monitoring for Signs of Suicide

By Lauran Neergaard
Associated Press
Monday, March 22, 2004; 11:25 AM

Patients on some popular antidepressants should be closely monitored for warning
signs of suicide, the government warned Monday in asking the makers of 10 drugs to
add the caution to their labels.

Although the Food and Drug Administration's investigation into the possible suicide
connection initially focused on children given the drugs, its warning is aimed at
both adult and pediatric use of the pills to alleviate depression.

It isn't clear yet that the drugs actually do lead to suicide, the FDA stressed.
After all, depression itself can lead to suicide.

But until that is settled, advisers to the FDA called last month for stronger
warnings to doctors and parents that the antidepressants may cause agitation,
anxiety and hostility in a subset of patients who may be unusually prone to rare
side effects.

On Monday, the FDA followed its advisers' recommendation and issued a public health
advisory putting doctors, patients, families and other caregivers on notice to be
particularly vigilant for signs of worsening depression or suicidal thoughts at the
beginning of anti-depressant therapy or whenever the dose is changed.

The drugs of concern are all newer-generation antidepressants: Prozac, Paxil,
Zoloft, Effexor, Celexa, Remeron, Lexapro, Luvox, Serzone and Wellbutrin. Most are
known to affect the brain chemical serotonin.

British health authorities sounded the alarm last year, saying long-suppressed
research suggests certain antidepressants might sometimes increase the risk of
suicidal behavior in children and teenagers. Because only one drug, Prozac, has been
proven to alleviate pediatric depression, Britain declared others -- drugs called
SSRIs and their close relatives -- unsuitable for depressed youth.

The FDA issued a caution on pediatric use last year, but Monday's action --
especially the addition of the warning to drug labels -- goes significantly further.

Dozens of anguished parents pleaded with FDA in a meeting last month to add such
warnings, citing preteens and teenagers who hanged themselves or slashed their
wrists shortly after starting the antidepressants. Parent after parent described
children who had become extremely agitated or anxious shortly after starting
the antidepressants, and seemingly sudden impulses that turned deadly.

Among 25 studies of the suspect medications involving 4,000 children and teens,
there were no completed suicides. But 109 patients experienced one or more possibly
suicide-related behaviors or attempts, the FDA says.

The studies varied dramatically in what was considered suicidal behavior, making a
clear link difficult, FDA scientists have contended. For example, among 19 patients
classified as cutting themselves, almost all were superficial, with little bleeding.

Worse, the youths most likely to commit suicide weren't allowed into those studies,
so existing data likely won't settle the issue, the FDA's scientific advisers have

Depression occurs in up to 10 percent of youth, and 1,883 10- to 19-year-olds killed
themselves in 2001. Some 1.8 million teenagers attempted suicide that year, a
quarter of them requiring medical attention, according to Columbia University
scientists who are helping the FDA's probe.

In 2002, almost 11 million prescriptions were dispensed to patients under 18 for
SSRIs and other newer antidepressants, to treat depression and a host of other
conditions, FDA said.

2004 The Associated Press